A recent study has identified a mono-chlorinated version of GBZ, sephin1, which retains the GBZ PPP1R15A inhibition activity, but without adrenoceptor activity [62] and it has also been shown to be effective in animal models of amyotrophic lateral sclerosis [62], Charcot-Marie-Tooth 1B (CMT1B) neuropathy [62] and multiple sclerosis [46]. Here, PPP1R15A is linked to amyotrophic lateral sclerosis.